Literature DB >> 22740043

Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.

Young-Min Lim1, Hee Kyung Park, Jae Seung Kim, Chong Sik Lee, Sun Ju Chung, Jimin Kim, Kwang-Kuk Kim.   

Abstract

Neurodegenerative overlap syndrome has been considered as a wide spectrum of motor neuron disease (MND), parkinsonism, or dementia. Specially, clinically overt parkinsonism occurs more often than expected in patients with motor neuron disease (MND), and diverse clinical manifestations of concurrent parkinsonism have been reported. We aimed to clarify clinical and functional imaging characteristics in patients with combined MND and parkinsonism. Of 732 patients diagnosed with MND over 22 consecutive years, eight patients (all men; mean age 62.8 years) exhibited parkinsonism. According to their parkinsonian features and presence of other neurologic signs including dementia, extraocular movement abnormalities, and cerebellar or autonomic dysfunction, they were classified into two groups: MND-parkinsonism (MND-P, n = 5) and MND-parkinsonism-plus syndrome (MND-Plus, n = 3). In the MND-P group, parkinsonism was asymmetric, dominated by resting tremor, and responsive to levodopa. [(18)F] N-(3-fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) positron emission tomography (PET) in two patients disclosed asymmetrically reduced uptakes in the dorsolateral putamen. In the MND-Plus group, parkinsonism was symmetric, with akinetic rigidity and postural instability dominance, and unresponsive to levodopa. [(18)F] FP-CIT PET scan in one patient showed decreased uptake in bilateral caudate nuclei and putamina. In conclusion, patients with MND and concurrent parkinsonism have heterogeneous clinical and imaging characteristics, which could be classified as features of PD and parkinsonism-plus syndrome. Patients with MND-P may have nigrostriatal dysfunction, and their parkinsonism may respond to levodopa treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740043     DOI: 10.1007/s10072-012-1139-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  31 in total

1.  Sporadic and familial parkinsonism and motor neuron disease.

Authors:  K Brait; S Fahn; G A Schwarz
Journal:  Neurology       Date:  1973-09       Impact factor: 9.910

Review 2.  Mechanisms underlying inflammation in neurodegeneration.

Authors:  Christopher K Glass; Kaoru Saijo; Beate Winner; Maria Carolina Marchetto; Fred H Gage
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

3.  Neurodegenerative overlap syndrome: Parkinsonism and motor neuron disorder.

Authors:  Akiko Imamura; Zbigniew Wszolek; Ryan Uitti
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

Review 4.  Mitochondrial pathobiology in Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

5.  Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes.

Authors:  Rebecca M Wolf Gilbert; Stanley Fahn; Hiroshi Mitsumoto; Lewis P Rowland
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

6.  123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

Authors:  A Antonini; R Benti; R De Notaris; S Tesei; A Zecchinelli; G Sacilotto; N Meucci; M Canesi; C Mariani; G Pezzoli; P Gerundini
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

7.  Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning.

Authors:  H Takahashi; B J Snow; M H Bhatt; R Peppard; A Eisen; D B Calne
Journal:  Lancet       Date:  1993-10-23       Impact factor: 79.321

8.  Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels.

Authors:  B J Snow; I Tooyama; E G McGeer; T Yamada; D B Calne; H Takahashi; H Kimura
Journal:  Ann Neurol       Date:  1993-09       Impact factor: 10.422

9.  Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case.

Authors:  Masayuki Shintaku; Kiyomitsu Oyanagi; Daita Kaneda
Journal:  Neuropathology       Date:  2007-06       Impact factor: 1.906

10.  Familial adult motor neuron disease: amyotrophic lateral sclerosis.

Authors:  D W Mulder; L T Kurland; K P Offord; C M Beard
Journal:  Neurology       Date:  1986-04       Impact factor: 9.910

View more
  2 in total

1.  Parkinsonian Syndromes in Motor Neuron Disease: A Clinical Study.

Authors:  Jacopo Pasquini; Francesca Trogu; Claudia Morelli; Barbara Poletti; Floriano Girotti; Silvia Peverelli; Alberto Brusati; Antonia Ratti; Andrea Ciammola; Vincenzo Silani; Nicola Ticozzi
Journal:  Front Aging Neurosci       Date:  2022-06-27       Impact factor: 5.702

2.  C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study.

Authors:  Johnathan Cooper-Knock; Antonina Frolov; J Robin Highley; Gavin Charlesworth; Janine Kirby; Antonio Milano; Judith Hartley; Paul G Ince; Christopher J McDermott; Tammaryn Lashley; Tamas Revesz; Pamela J Shaw; Nicholas W Wood; Oliver Bandmann
Journal:  Neurology       Date:  2013-07-24       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.